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Introduction: Modified fractionation radiotherapy (RT), delivering 
multiple fractions per day or shortening the overall treatment time, 
improves overall survival for non -small-cell lung cancer (NSCLC) 
patients compared with conventional fractionation RT (CRT). 
However, its cost effectiveness is unknown. Therefore, we aimed to 
examine and compare the cost effectiveness of different modified RT 
schemes and CRT in the curative treatment of unresected NSCLC 
patients.
Methods: A probabilistic Markov model was developed based on 
individual patient data from the meta-analysis of radiotherapy in 
lung cancer (N = 2000). Dutch health care costs, quality-adjusted life 
years (QALYs), and net monetary benefits (NMBs) were compared 
between two accelerated schemes (very accelerated RT [VART] and 
moderately accelerated RT [MART]), two hyperfractionated schemes 
(using an identical (HRTI) or higher (HRTH) total treatment dose than 
CRT) and CRT.
Results: All modified fractionations were more effective and cost-
lier than CRT (1.12 QALYs, €24,360). VART and MART were most 
effective (1.30 and 1.32 QALYs) and cost €25,746 and €26,208, 
respectively. HRTI and HRTH yielded less QALYs than the acceler-
ated schemes (1.27 and 1.14 QALYs), and cost €26,199 and €29,683, 
respectively. MART had the highest NMB (€79,322; 95% confidence 
interval [CI], €35,478-€133,648) and was the most cost-effective 
treatment followed by VART (€78,347; 95% CI, €64,635-€92,526). 
CRT had an NMB of €65,125 (95% CI, €54,663-€75,537). MART 
had the highest probability of being cost effective (43%), followed by 
VART (31%), HRTI (24%), HRTH (2%), and CRT (0%).
Conclusion: Implementing accelerated RT is almost certainly more 
efficient than current practice CRT and should be recommended as 
standard RT for the curative treatment of unresected NSCLC patients 
not receiving concurrent chemo-radiotherapy.
Key Words: Radiotherapy, Dose fractionation, Non–small-cell lung 
cancer, Cost–benefit analysis, Markov chain.
(J Thorac Oncol 2013;8:1295–1307)
Non–small-cell lung cancer (NSCLC) comprises 85% of all lung cancer, which is the third most diagnosed form 
of cancer and causes the greatest number of cancer deaths.1,2 
Radiotherapy (RT) with or without chemotherapy is increasingly 
being used in the curative treatment for unresected NSCLC.3 
The therapeutic effect of radiation alone in lung cancer follows 
a clear dose–response relationship (i.e., higher biological doses 
lead to better local tumor control).4–6 Hence, as recently shown 
by an individual patient meta-analysis,7 modified fractionation 
RT schemes, with increased biological dose, have the ability to 
improve overall survival (OS) compared with conventional RT 
schedules (hazard ratio [HR], 0.88). Additionally, modified RT 
increased the risk of acute esophageal toxicity.7
With regard to the scarcity of resources and accelerating 
costs of cancer care, it is increasingly important to consider the 
cost–benefit ratio of (new) treatments to guide decision mak-
ing.8,9 Economic evaluations are frequently performed using 
decision-analytic modeling to synthesize different sources of 
evidence (e.g., effectiveness, patient-reported outcomes and 
costs), compare the cost effectiveness of competing inter-
ventions and support decision making under uncertainty.9 
As cost-effectiveness estimates are inevitably surrounded 
by uncertainty, it is essential to characterize uncertainty in 
economic evaluations.9 Although parameter uncertainty (as 
exact estimates for parameters such as effectiveness are often 
unknown) is frequently acknowledged in decision-analytic 
modeling, patient heterogeneity is often ignored.10,11 The 
objective of the present study is to perform a cost-effective-
ness analysis comparing multiple modified fractionation RT 
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schemes with conventional fractionation RT (CRT) in the 
curative treatment of unresected NSCLC while taking into 
account both parameter uncertainty and patient heterogeneity.
MATERIALS AND METHODS
Meta-Analysis of RT in Lung Cancer
The Meta-Analysis of Radiotherapy in Lung Cancer 
(MAR-LC) database was used as the primary data source. 
This database consists of individual patient data from 12 ran-
domized clinical trials (RCTs) that compared conventional 
and modified fractionated RTs.7 The 10 RCTs with a popu-
lation of unresected NSCLC patients were selected for the 
present study. These RCTs accrued a total of 2000 patients 
between 1989 and 2006 (median follow-up, 6.9 years). In 
four trials, the same chemotherapy was administered in both 
arms either concomitantly with RT (2 trials) or as induction 
chemotherapy (2 trials). No chemotherapy was given in the 
other RTCs. Most patients were men (75%), aged 60 to 69 
years (42%), and had squamous cell carcinoma (SCC; 60%) 
and stage III disease (83%). Performance status was good 
(Eastern Cooperative Oncology Group performance status = 
0) for 43% of the patients.
Markov Model Description
A probabilistic decision-analytic Markov cohort model 
was developed. To compare competing interventions, this 
model aims to reflect the course of a disease using a hypotheti-
cal cohort of patients who transit between mutually exclusive 
health states.9 These health states were based on whether patients 
were alive and presence of toxicity (Fig. 1). Subsequently, the 
expected costs and effects were estimated for conventional 
fractionated RT and four types of modified fractionation RT. 
These modified fractionation schemes are based on two types 
of modified fractionation and their combination: (1) acceler-
ated RT schemes, which consist of a reduced overall treatment 
time (OTT) compared with conventional fractionation and 
(2) hyperfractionated RT schemes, which consist of a higher 
number of fractions with a smaller dose per fraction compared 
with conventional RT. Five schemes were compared using the 
MAR-LC database (Appendix 1, Supplemental Digital Content 
1, http://links.lww.com/JTO/A451):
1. CRT (10 trials; N = 944): five weekly fractions of 1.8 to 
2.0 Gy, accumulating to a total treatment dose (TTD) of 
60 to 70 Gy.
2. Very accelerated RT (VART; 6 trials; N = 700): reduced OTT 
with more than or equal to 50%, using an identical (±5%) or 
lower (5%–10%) TTD compared with CRT (OS HR, 0.88 
[95% confidence interval (CI) 0.78–0.98] versus CRT).7
3. Moderately accelerated RT (MART; 1 trial; N = 29): reduced 
OTT with 14% to 49%, using a TTD identical (±5%) to CRT 
(OS HR, 0.90 (95% CI, 0.52–1.54) versus CRT).7
4. Hyperfractionated RT using identical TTD (HRTI; 2 tri-
als, N = 164): the average dose per fraction is decreased 
to 1.75 Gy or lesser, using a TTD identical (±5%) to CRT 
(OS HR: 0.87 (95% CI, 0.69–1.10) versus CRT).7
5. Hyperfractionated RT using higher TTD (HRTH; 1 trial; 
N = 163): the average dose per fraction is decreased to 
1.75 Gy or lesser, using a higher (5%–15%) TTD than 
CRT (OS HR, 0.92 [95% CI, 0.74–1.15] versus CRT).7
A lifetime time horizon and a cycle time of 1 month 
were used. Additionally, a half-cycle correction was applied. 
Future costs and effects were discounted by rates of 4.0% and 
1.5%, respectively, according to the Dutch pharmaco-eco-
nomic guideline.
Because a model is a simplified representation of real-
ity, assumptions about reality are inherent to modeling. The 
main assumptions were:
1. On the basis of an analysis of the Radiation Therapy 
Oncology Group database, acute toxicity was assumed 
to increase from start of radiotherapy up to 3 months 
after start of radiotherapy and to reverse afterwards for 
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FIGURE 1.  Diagrammatical represen-
tation of the Markov model structure. 
*The numbers (1 and 2) next to the 
arrows correspond to the Weibull 
models in Appendix 2 (Supplemental 
Digital Content 1, http://links.lww.
com/JTO/A451). †Acute toxicity 
included grade 3 or higher pulmo-
nary toxicity, esophageal toxicity, and 
hematological toxicity (see Appendix 
3 [Supplemental Digital Content 1, 
http://links.lww.com/JTO/A451] for 
the corresponding logistic regres-
sion models). ‡Late toxicity included 
grade 3 or higher pulmonary toxic-
ity and esophageal toxicity (Table 1). 
§Noncancer mortality was defined as 
deaths resulting from causes other 
than cancer and not occurring after 
disease progression.
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all patients.12 Late toxicity was assumed to be irrevers-
ible, to begin 3 months after start of RT and to increase 
in frequency up to 1.5 years, with the assumption that it 
had plateaued.12
2. There is no overlap between toxicities, that is, a patient 
can only have one toxicity and not, for example, both pul-
monary and esophageal toxicities concurrently. However, 
one patient can have different acute and late toxicities. 
No overlap between toxicities was assumed because 
there was only limited overlap in the MAR-LC database 
(3.1% for acute and 0.1% for late toxicity). Incorporating 
overlapping toxicities would unnecessarily increase the 
complexity and hence decrease the transparency of the 
model.
3. As mentioned above, modified RT may reduce noncan-
cer mortality (most likely because of differences in treat-
ment-related death).7 Nevertheless, we conservatively 
assumed that there is no difference in noncancer mortal-
ity between the RT schemes. This was assumed because 
noncancer mortality, which included treatment-related 
deaths, was not reported for MART.
Transition Probabilities
Time-dependent survival probabilities were estimated 
by means of parametric survival models, using a Weibull 
distribution (Appendix 2, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A451).13 Separate Weibull regres-
sion models were developed for noncancer mortality and 
cancer mortality. Logistic regression models were developed 
to estimate acute toxicity (grade ≥3) probabilities, separately 
for acute pulmonary, esophageal, and hematological toxicity 
(Appendix 3, Supplemental Digital Content 1, http://links.
lww.com/JTO/A451). All regression models were strati-
fied by trial to preserve randomization and obtain unbiased 
estimates.14 Potential heterogeneity in baseline risks was 
acknowledged through these regression models using the 
following covariates: treatment arm (CRT; VART; MART; 
HRTI; HRTH), sex (male; female), age (≤59 years; 60–69 
years; ≥70 years), performance status (mild; good), histol-
ogy (SCC; non-SCC), and disease stage (I/II; IIIA; IIIB). 
All variables were included in the initial model as categori-
cal variables. Selection of covariates was performed as 
described by Hosmer et al.15 except for the treatment arm 
variable. The treatment arm variable was not included in 
the Weibull model to predict noncancer mortality, and was 
always included in the Weibull regression model that predicts 
cancer mortality. Individual characteristics were needed to 
calculate the acute toxicity probabilities, using the logistic 
regression models. For this purpose, a hypothetical cohort of 
individual patients was replicated based on average charac-
teristics and their correlations from the MAR-LC database 
TABLE 1.  Input Parameters: Probabilities and Health State Utility
Parameter Estimated 
Value
SE Distribution Source
Probabilities
  Probability of noncancer mortality Dependent on time and patient characteristics Appendix 2
  Probability of cancer mortality Dependent on time and patient characteristics Appendix 2
  Probability of acute pulmonary toxicity Dependent on patient characteristics Appendix 3
  Probability of acute esophageal toxicity Dependent on patient characteristics Appendix 3
  Probability of acute hematological toxicity Dependent on patient characteristics Appendix 3
  Probability of late pulmonary toxicitya 15.4% 1.2% Beta MAR-LC
  Probability of late esophageal toxicitya 3.3% 0.6% Beta MAR-LC
Health state utility
  No recurrence No toxicity 0.800 0.029 Beta 16
Acute hematological toxicityb 0.710 16,33
Acute pulmonary toxicityc 0.493 0.075 Beta 16
Acute esophageal toxicityc 0.493 0.075 Beta 16
Late pulmonary toxicityc 0.493 0.075 Beta 16
Late esophageal toxicityc 0.493 0.075 Beta 16
  Recurrence No toxicity 0.794 0.038 Beta 16
Acute hematological toxicityb 0.704 16,33
Acute pulmonary toxicityc 0.129 0.061 Beta 16
Acute esophageal toxicityc 0.129 0.061 Beta 16
Late pulmonary toxicityc 0.129 0.061 Beta 16
Late esophageal toxicityc 0.129 0.061 Beta 16
aIt was assumed that late toxicity increases from 3 months after start radiotherapy up to 18 months after start of radiotherapy to the total probability. The monthly probability was 
then calculated from the total probability using the following formula:9
p p 1 month  1  e ln 1   total   ( ) ( ( ) / )= − − ( ) × 1 15 .
bThis health state utility was calculated based the utilities without toxicity, as given by Grutters et al.,16 and a disutility from the study by Nafees et al.33
cIt was assumed that patients with acute or late esophageal or pulmonary toxicity had the same utility scores.
NSCLC, non–small-cell lung cancer; MAR-LC, Meta-Analysis of Radiotherapy in Lung Cancer.
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(Appendix 3, Supplemental Digital Content 1, http://links.
lww.com/JTO/A451).
To estimate late pulmonary and esophageal toxicity 
(grade ≥3), the proportions from the MAR-LC database 
were used. Consistent with the meta-analysis, late toxicity 
was assumed to be equal for all comparators (Table 1).7 All 
parameters retrieved from the MAR-LC database were com-
puted in the Department of Biostatistics and Epidemiology 
of Institut de Cancérologie Gustave-Roussy by Lueza and 
Ramaekers.
Effects and Costs
Utility scores were used as effect measure. Utility is 
a single score measure for generic health-related quality of 
life and ranges from 0 (death) to 1 (full health). These utility 
scores were combined with life expectancy to calculate qual-
ity-adjusted life years (QALYs). Utility scores were derived 
from a Dutch cross-sectional study (n = 260),16 which used the 
Euroqol-5D17 questionnaire. Patients with unresected NSCLC 
(n = 85) were selected from this study (Table 1).
Patients who died because of NSCLC in the Markov model 
were assigned a disutility. This was the average disutility for recur-
rent disease (0.152) multiplied by the average life expectancy after 
recurrent disease (6 months in the MAR-LC database).
Costs were calculated using the Dutch health care per-
spective and converted to the 2011 price level, based on price 
indices from Statistics Netherlands (CBS). Resource use and 
unit prices are reported in Table 2.
Markov Model Analysis
Expected life years (LYs), QALYs, costs and net mon-
etary benefit (NMB) were estimated for all comparators. The 
NMB was calculated by multiplying the number of QALYs 
with the ceiling ratio and subtracting the total costs. The treat-
ment strategy with the highest NMB is considered as most 
cost effective. We adopted a ceiling ratio of €80,000, because 
this is the informal ceiling ratio for a high burden of disease 
in The Netherlands.18 The incremental cost-effectiveness ratio 
(ICER) was calculated by dividing the incremental costs by 
the incremental QALYs. The ICER represents the costs of 
an additional QALY gained and was used to estimate the 
cost effectiveness of a treatment (1) opposed to CRT and (2) 
opposed to the next best alternative. A treatment is deemed 
cost effective when its ICER is below the ceiling ratio.
The Markov model was analyzed in Microsoft Excel 
2003 (computer software; Microsoft Corporation, Redmond, 
WA). The analyses required to retrieve the input parameters 
were performed in SAS version 9.2 (SAS Institute, Cary, NC), 
except the Weibull analysis, which was performed in R ver-
sion 2.13.1 (open-source computer software; R Foundation, 
Vienna, Austria), as SAS did not support stratification by trial 
in this analysis.
Parameter Uncertainty
To explore the impact of parameter uncertainty on the 
estimated (cost) effectiveness, probabilistic sensitivity analy-
sis was performed using Monte Carlo simulation (15,000 iter-
ations).9 For this purpose, a distribution was assigned to the 
input parameters (Tables 1 and 2). The Weibull and logistic 
regression models were included using Cholesky decomposi-
tions.9 Cost-effectiveness acceptability curves were created to 
show for different ceiling ratios the probability that a treat-
ment is most cost effective.9
Because the estimated cost effectiveness is surrounded 
by uncertainty it is possible that based on current informa-
tion, the wrong decision is being made. The expected value of 
perfect information (EVPI) analysis quantifies the costs of this 
decision uncertainty. It estimates the value of further research 
to gain knowledge of the true parameter values.9 Thus, the 
EVPI represents the upper limit that society should be will-
ing to pay to reduce decision uncertainty and inform the deci-
sion in the future.9 The EVPI per patient was multiplied by the 
effective population in the next 5 years (expected lifespan of 
the technology) and discounted by a rate of 4% to calculate 
the population EVPI. The effective population was calculated 
based on a yearly incidence of 8661 NSCLC patients in The 
Netherlands (Dutch Cancer Registration, 2010) minus the 
estimated proportion of resected NSCLC patients (20%) and 
the estimated proportion with metastatic disease among unre-
sected patients (40%), this resulted in an annual population of 
4157 patients. To identify the most valuable research topics, 
the expected value of partial perfect information (EVPPI) for 
(groups of) parameters was calculated.
Heterogeneity
The expected value of individualized care (EVIC) was 
calculated to examine the impact of patient heterogeneity on 
cost effectiveness.19,20 The EVIC estimates the value of provid-
ing the optimal treatment for each individual instead of the 
average best treatment for all patients. The same hypothetical 
cohort of individual patients as for the logistic regressions was 
used for this calculation (Appendix 3, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A451). The EVIC per 
patient was estimated by calculating (1) the NMB of the 
optimal treatment per patient (NMB
patient_max
); (2) the NMB 
of the average best treatment (NMB
average_max
); (3) EVIC
patient
 
= NMB
patient_max
−NMB
average_max
 for all individual patients; and 
(4) calculating the average EVIC
patient
 and multiplying it by the 
effective population.
RESULTS
Expected survival ranged from 20 months for CRT (1.63 
LYs) and HRTH (1.66 LYs) to 22 months for HRTI (1.83 LYs), 
up to 23 months for VART (1.88 LYs) and MART (1.90 LYs). 
MART was also the most effective treatment (1.32 QALYs) 
in terms of QALYs, followed by VART (1.30 QALYs), HRTI 
(1.27 QALYs), HRTH (1.14 QALYs), and CRT (1.12 QALYs).
HRTH was most costly (€29,683), followed by MART 
(€26,208), HRTI (€26,199), VART (€25,746), and CRT 
(€24,360). Costs differences were mainly because of differ-
ences in the number of fractions leading to differences in pri-
mary treatment costs.
CRT was both the least effective and least expensive 
treatment. Compared with CRT, all comparators except HRTH 
(ICER: €228,852) were cost effective, with ICERs ranging 
between €7,592 (VART) and €12,379 (HRTI).
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TABLE 2.  Input Parameters: Resource Use and Costs
Parameter Estimated Value SE/Range Distribution Source
Primary treatment costs
  Time per fraction of radiotherapy (min) 10 8–18 Beta PERT EO
  Costs per 10 min of radiotherapy €233 €194–€291 Beta PERT 34
  Number of fractions for CRT 30 0.2 Gamma MAR-LC
Costs of CRT €6,940
  Number of fractions for VART 36 0.2 Gamma MAR-LC
Costs of VART €8,290
  Number of fractions for MARTa 38 0.2 Gamma MAR-LC
Costs of MART €8,940
  Number of fractions for HRTIa 38 0.2 Gamma MAR-LC
Costs of HRTI €8,940
  Number of fractions for HRTH 53 1.1 Gamma MAR-LC
Costs of HRTH €12,237
Event costs
  Acute pulmonary toxicity costs (≥grade 3)
   Probability of hospitalization (%) 2.5 0.3 Beta EO
   Days of hospital admission 11 2.0 Gamma 35
   Costs of hospital admission (per day) €463 Fixed 36
   Medication costs €22 Fixed CvZ
  Acute pulmonary toxicity costs €147
  Acute esophageal toxicity costs (≥grade 3)
   Days of hospital admission 2 0.3 Gamma EO
   Costs of hospital admission (per day) €463 Fixed 36
   Days of tube feeding when hospitalized 21 2.0 Gamma EO
   Costs of tube nutrition per day €18 Fixed MP
   Costs of placing and removing tube €269 Fixed NZa
   Medication costs for acute esophageal toxicity €31 Fixed CvZ
  Acute esophageal toxicity costs €1,604
Acute hematological toxicity costs (≥grade 3)
  Costs of an episode of febrile neutropenia €3,754 €1241 Gamma 37
Mortality costs (costs of last life-year before dying)
Cancer mortality €22,793 €2000b Gamma 38
Noncancer mortality €16,246 €2000b Gamma 38
Health state costs
  Follow-up costs
   Costs per follow-up visit €73 Fixed 36
   Number of follow-up visits in first year 4 Fixed NSCLC guideline
  Monthly costs of follow-up first year €24
   Number of follow-up visits in second year 2 Fixed NSCLC guideline
  Monthly costs of follow-up second year €12
   Number of follow-up visits after second year 1 Fixed NSCLC guideline
  Monthly costs of follow-up after second year €6
Late toxicity costs
  Yearly costs of irreversible dyspnea ≥ grade 3 €1099 €100b 35
  Monthly costs of irreversible dyspnea ≥ grade 3 €92
aBecause of a lack of data, the number of fractions was assumed to be 96% of the theoretical number of fractions (as observed on average for the other comparators) and the SE 
from very accelerated radiotherapy was used.
bSE was based on expert opinion.
EO, expert opinion; MP, market price; NZa, Nederlands Zorg Authoriteit/Dutch Healthcare Authority; CvZ, College voor Zorgverzekeringen/Health Care Insurance Board; 
CRT, conventional fractionation radiotherapy; MAR-LC, Meta-Analysis of Radiotherapy in Lung Cancer; VART, very accelerated radiotherapy; MART, moderately accelerated 
radiotherapy; HRTI, identical hyperfractionated radiotherapy; HRTH, higher hyperfractionated radiotherapy; NSCLC, non–small-cell lung cancer.
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HRTH was both more effective (0.02 QALYs) and expen-
sive (€5,323) than CRT. This resulted in an ICER of €228,852. 
Given the ceiling ratio of €80,000 per QALY gained, HRTH 
was not cost effective opposed to CRT. HRTI was also more 
effective (0.15 QALYs) and expensive (€1,839) than CRT, 
leading to an ICER below the ceiling ratio (€12,379). HRTI 
was thus cost effective opposed to CRT. VART was more 
effective (0.03 QALYs) and less expensive (€453) and thus 
dominated HRTI. MART was more effective (0.02 QALYs) 
and more expensive (€462) than VART. The calculated ICER 
(€25,716) was below the ceiling ratio. Thus, MART is the 
most cost-effective RT scheme (Table 3).
Figure 2 and Appendix 4 (Supplemental Digital Content 
1, http://links.lww.com/JTO/A451) show the uncertainty sur-
rounding the results. Taking into account this uncertainty, 
MART had the highest probability of being cost effective (43%), 
followed by VART (31%), HRTI (24%), HRTH (2%), and CRT 
(0%; Fig. 2). Additionally, the estimated EVPI was €228 mil-
lion (Fig. 3). More specifically, the EVPPI indicated that fur-
ther research would be most valuable for the primary treatment 
costs of MART (€8.2 million) and cancer mortality after VART 
(€6.7 million) and MART (€5.4 million). The EVIC showed a 
value of individualizing care of €0.1 million (Fig. 3).
DISCUSSION
All modified RT schemes were more effective and costlier 
than CRT. Although MART was the most cost-effective treat-
ment strategy, the differences between comparators were small, 
and all CIs for the incremental costs and effects were overlap-
ping (Table 3). Therefore, it is uncertain which modified fraction-
ation strategy is most cost effective. Moreover, estimated survival 
after MART was based on only one study with a small number 
of patients (n = 58). Despite this uncertainty, modified fraction-
ation RT in general is likely (>99%) cost-effective compared with 
CRT, and accelerated schemes are likely to be the most effec-
tive and cost-effective modified fractionation schemes. However, 
it is unclear which accelerated fractionation scheme is deemed 
optimal. The comparison of MART versus VART resulted in a 
51% probability for MART and 49% probability for VART of 
being cost effective (Appendix 4, Supplemental Digital Content 
1, http://links.lww.com/JTO/A451). Additionally, in the individ-
ual patient meta-analysis, heterogeneity in the relative treatment 
effect between the different RT schemes was not demonstrated.7 
In this article we examined patient heterogeneity based on differ-
ences in baseline risk, and found that there was relatively little 
value to individualize care (i.e., to provide different treatments to 
different patients). Instead, it would be more valuable to perform 
further research to reduce parameter uncertainty, specifically for 
primary treatment costs of MART and cancer mortality after 
VART and MART.
Our study was the first to assess the cost effectiveness of 
several modified RT schemes in NSCLC. In one prior analysis, 
which also used a Markov model, an ICER of €11,576 was 
estimated for continuous hyperfractionation accelerated radio-
therapy (CHART) compared with CRT; thus leading to the 
conclusion that CHART is likely cost effective in Belgium.21 
This CHART trial was included in the VART arm in our study. 
The comparison in our study of VART and CRT would result in 
a slightly more beneficial ICER for VART of €7,592.
The limitations of present study were, first, that the health 
care perspective was used instead of the societal perspective. 
Therefore, productivity losses at work were not incorporated. 
Because 48% of the study population was above the Dutch pen-
sionable age at the beginning of the treatment, no large differences 
between the perspectives are expected. Second, all MAR-LC tri-
als compare modified RT and CRT (Appendix 1, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A451). Hence, 
the comparisons between different modified fractionated RT 
TABLE 3.  Incremental Analyses (Sorted by QALY)
Treatment
Expected Outcomes (95% CI)a Compared with CRT (95% CI)a Compared with Next Cost-Effective Strategy (95% CI)a
QALYs Costs NMB
Incremental 
QALYs
Incremental 
Costs
ICER 
Costs/ 
QALY Comparator
Incremental 
QALYs
Incremental  
Costs
ICER Costs/ 
QALY
CRT 1.12 (1.00– 
1.24)
€24,360 
(€21,173– 
€28,110)
€65,125 
(€54,663– 
€75,537)
— — — — — — —
HRTH 1.14 (0.90– 
1.42)
€ 29,683 
(€25,536– 
€35,208)
€61,663 
(€40,967– 
€84,360)
0.02 (−0.20  
-0.28)
€5,323 
(€3,907– 
€7,533)
€228,852 CRT 0.02 (−0.20  
-0.28)
€5,323  
(€3,907– 
€7,533)
€228,852
HRTI 1.27 (1.00– 
1.57)
€26,199 
(€22,714– 
€30,523)
€75,170 
(€53,320– 
€99,989)
0.15 (−0.11  
-0.44)
€1,839 
(€1,212– 
€2,699)
€12,379 CRT 0.15 (−0.11  
-0.44)
€1,839  
(€1,212– 
€2,699)
€12,379
VART 1.30 (1.14– 
1.47)
€25,746 
(€22,370– 
€29,861)
€78,347 
(€64,635– 
€92,526)
0.18 (0.05– 
0.32)
€1,386  
(€957– 
€1,982)
€7,592 HRTI 0.03 (−0.29  
-0.33)
−€453 
(−€908  
to −22)
Dominant
MART 1.32 (0.78– 
1.99)
€26,208 
(€22,690– 
€30,571)
€79,322 
(€35,478– 
€133,648)
0.20 (−0.35  
to 0.87)
€1,848  
(€895– 
€2,845)
€9,214 VART 0.02 (−0.55  
-0.70)
€462  
(−€347 to 
€1,168)
€25,716
aThe mean and 95% CI were based on the probabilistic sensitivity analysis (see Appendix 4 for the cost-effectiveness planes corresponding to the comparisons).
QALYs, quality-adjusted life years; NMB, net monetary benefit; ICER, incremental cost-effectiveness ratio; CI, confidence interval; CRT, conventional fractionation 
radiotherapy; HRTI, identical hyperfractionated radiotherapy; HRTH, higher hyperfractionated radiotherapy; VART, very accelerated radiotherapy; MART, moderately accelerated 
radiotherapy.
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schemes are based on indirect evidence. Although synthesis of 
head-to-head comparisons of RCTs provides the most valid evi-
dence of treatment effectiveness, it has been recommended that 
indirect treatment comparisons should be considered if direct 
evidence is unavailable.22,23 The comparisons were stratified 
by trial, comparing patients only within each trial (preserving 
randomization), to obtain unbiased estimates.14 Third, concomi-
tant chemo-radiotherapy is the current standard although this 
was administered in only two of the ten included trials. Only 
one study (NCCTG 94242) used cisplatin-doublet chemother-
apy during RT, which is at present considered to be the stan-
dard concurrent schedule. We were therefore unable to examine 
FIGURE 2.  Cost effectiveness acceptability curves. The vertical line represents the ceiling ratio that was adopted in our analyses 
(€80,000 per QALY gained). CRT, conventional fractionation radiotherapy; VART, very accelerated radiotherapy; MART, moder-
ately accelerated radiotherapy; HRT, hyperfractionated radiotherapy.
FIGURE 3.  Expected value of individualized care and expected value of perfect information. The vertical line represents the 
ceiling ratio that was adopted in our analyses (€80,000 per quality-adjusted life year gained).
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the impact of concomitant chemo-radiotherapy. Nevertheless, 
compared with CRT the benefit of modified RT with chemo-
therapy on OS (HR = 0.92; 95% CI, 0.77–1.10) was not signifi-
cantly (interaction p = 0.57) lower than for modified RT without 
chemotherapy (HR = 0.87; 95% CI, 0.78–0.97).7 Additionally, 
although this was not observed in a recent phase II study,24 modi-
fied RT delivered concurrently with chemotherapy may increase 
acute side effects in comparison with concurrent chemotherapy 
with conventional RT. In case of increased toxicity when pro-
viding concomitant chemo-radiotherapy, the incremental costs 
for modified RT compared with CRT might on the one hand 
increase because of potentially increased toxicity management 
costs. On the other hand, it might result in lower incremental 
costs, for instance because of interruption and stopping of both 
chemotherapy and RT (before finishing all chemotherapy cycles 
and RT fractions). Thus, if chemotherapy is added to all included 
trials, the incremental effects can be expected to be similar and 
the impact on incremental costs would be unclear. This issue 
should be addressed in future (economic) studies. Fourth, to 
avoid unnecessary complexity in the model, it was decided not 
to incorporate overlapping toxicities (as described in the Model 
Description section). Despite this simplification of the model, 
the total occurrence of the acute and late toxicities in the present 
model would be equal to a more complex model incorporating 
overlap between toxicities. Also, as described in the Methods 
section, overlap between available toxicities in the MAR-LC 
database was small. Therefore, considering this low proportion 
of overlap between toxicities and the equivalence between total 
occurrence of toxicity, this model assumption is unlikely to have 
a large impact on the study results. Finally, the applied survival 
of 6 months after recurrence, to calculate the disutility for can-
cer mortality, could be criticized in view of the median survival 
of 10 to 12 months in newly diagnosed stage IV NSCLC.25 
Nevertheless, this was a conservative assumption, that is, longer 
survival after recurrence, and thus a higher disutility, will favor 
the modified RT treatments because these have less NSCLC 
deaths (and thus fewer disutilities).
It is likely that with recent advancements in RT techniques, 
the same level of acceleration can be given safely in fewer frac-
tions, that is, 24 fractions instead of 38 fractions (as for VART 
and MART).26,27 This could reduce the costs (because of the lower 
number of fractions) while maintaining the survival benefit of 
accelerated RT. HRTI, the third most cost-effective option in our 
analysis, applies split-course RT. Although this was not observed 
in the individual patient meta-analysis,7 it is widely believed to be 
less efficient than continued RT schemes. As a result, split-course 
RT is rarely used nowadays.28 Also, concurrent chemotherapy 
and CRT is nowadays the treatment of choice for good perfor-
mance status patients with locally advanced NSCLC.29 However, 
as many patients are not eligible for concomitant chemo-radio-
therapy treatment,30 sequential chemotherapy and accelerated RT 
seems a promising treatment option. In the present analysis we 
were unable to examine the role of chemotherapy in combination 
with modified fractionation RT. Although the benefit of modified 
RT with and without chemotherapy did not differ significantly,7 
the results of RTOG 9410 and RTOG 0617 caution against 
assuming that modifying conventional concomitant chemo-
radiotherapy will improve the therapeutic ratio.31,32 For sequential 
chemotherapy and RT, there are no indications that there would 
be an interaction between both modalities for toxicity. Hence, the 
present study results are probably most applicable to patients not 
receiving concomitant chemo-radiotherapy. Studies examining 
the role of modified fractionation RT combined with concomi-
tant chemotherapy are warranted. This includes examining for 
instance whether it is safe to provide chemotherapy concurrently 
with accelerated RT, whether the benefits of modified fraction-
ation are preserved in case of concurrent chemo-radiotherapy, 
and whether other well-studied27 types of accelerated once-daily 
high-dose RT are cost effective.
In conclusion, it remains uncertain which modified 
scheme is most cost effective and it is unclear whether the 
study results can be extrapolated to modified RT combined 
with concomitant chemotherapy. Hence, further research 
comparing the cost effectiveness of different types of modified 
RT and examining the role of chemotherapy might be valu-
able. Nevertheless, implementing accelerated RT is almost 
certainly more cost effective than current practice (CRT) for 
patients treated with sequential chemo-radiotherapy or RT 
alone. Hence, waiting for more evidence before implementing 
accelerated RT (without concomitant chemotherapy) would 
lead to health benefits forgone. In addition, if future evidence 
would show that accelerated RT is not the most cost-effective 
RT type, the forgone implementation costs (sunk costs) are 
expected to be low. Therefore, despite available uncertainty, 
it is encouraged to adopt accelerated RT for the curative 
treatment of unresected NSCLC patients who do not receive 
concurrent chemo-radiotherapy and examine its role in the 
context of concurrent chemo-radiotherapy.
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APPENDIx 1. Classification of MAR-LC Trials
BED, biologic effective dose (average in case of mul-
tiple trials); CRT, conventional fractionation radiotherapy; 
MART, moderately accelerated radiotherapy; HRTI, identical 
hyperfractionated radiotherapy; HRTH, higher hyperfraction-
ated radiotherapy; MAR-LC, Meta-Analysis of Radiotherapy 
in Lung Cancer.
CRT
MART
VART
HRTH
HRTI
6 trials 
(N = 1296)
BED CRT: 57.7
BED VART: 61.5
1 trial 
(N = 326) 
B
ED
 CRT:
 55.5
B
ED
 M
A
RT:
 52.5
2 trials 
(N = 320)
BED CRT: 55.5
BED MART: 61.9 
1 trial 
(N = 58)
B
ED
 CRT:
 62.7
B
ED
 M
A
RT
: 68.5
10 trials (N = 2000)
APPENDIx 2. Input Parameters for Survival
The Weibull models were constructed according to 
the intention-to-treat principle using the following covari-
ates: treatment arm (CRT; VART; MART; HRTI; HRTH), sex 
(male; female), age (≤59; 60–69; ≥70 years), performance 
status (mild; good), histology (SCC; non-SCC) and disease 
stage (I/II; IIIA; IIIB). All variables were included in the ini-
tial model as categorical variables. Selection of covariates was 
performed as described by Hosmer et al.,1 except for the treat-
ment arm variable. This variable was not included in the equa-
tion to predict noncancer mortality, and was always included 
in the model for cancer mortality. The parameterization of the 
Weibull model is as follows:
 S t e( )= −λ
αt  (1)
Where S(t) = survival probability at time t. The shape 
parameter (α) could be retrieved from the analysis output. 
Lambda (λ), the event rate parameter, was calculated by the sum 
of all coefficients multiplied by the accompanying covariates (X): 
 
λ β β
β
    X  
 X
Intercept Treament arm Treatment arm
Age 6 69
= +
+ −0    X  
 X 
Age 6 69 Age 7 Age 7
Female Female Perform
0 0 0− ++ +
+ +
β
β β ance status good Performance status good
Histology Squam
X
+β ous cell Histology Squamous cell
Disease Stage IIIA Dise
X
X+β ase Stage IIIA Disease Stage IIIB Disease Stage IIIBX+β
 (2)
The coefficients (β) for all covariates were retrieved from 
the analysis output. The coefficient for the intercept was calculated 
based on the shape (α) and scale parameters from the R output:
 βIntercept  Ln scale   shape= − ( ) ×  (3)
One essential statistical technique when analyzing 
multiple trials is stratification by trial, which guarantees that 
patients are compared within each trial and not across trials.2 
The Weibull model was stratified by trial, which resulted in 
separate scale and shape parameters for each trial. The different 
scale and shape parameters were pooled using a random-effects 
model.3 Subsequently, all coefficients were multiplied by the 
accompanying average covariates to calculate λ. For instance, 
the proportion of female patients X
Female
 was multiplied by the 
coefficient for female β
Female
. The time-dependent transition 
probability between two cycles (between t
1
 and t
2
), was then 
calculated using the following formula (derived from Eq. 1):
 S t t e t t( ) ( )2 1
1 2− − −= λ
α α
 (4)
Estimated Regression Coefficients for Survival Probabilities
Parameter
Equation 1: Probability 
of Cancer Mortality 
(1644 Events)
Equation 2: Probability 
of Noncancer Mortality 
(205 Events)
Estimated 
Value SE
Estimated 
Value SE
Model characteristics
  Model distribution Weibulla Weibulla
  Shape (α) 1.093 0.200 0.920 0.372
  Ln(scale) 6.635 0.053 8.389 0.147
  Interceptb −7.252 −7.722
Explanatory baseline characteristicsc
  Treatment arm
  VART −0.176 0.064
  MART −0.169 0.276
  HRTI −0.137 0.128
  HRTH −0.022 0.119
  Age (yr)
(Continued)
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(Continued)
   60–69 −0.123 0.061 0.378 0.219
   70+ −0.149 0.070 0.688 0.223
  Sex
   Female −0.149 0.059 −0.372 0.188
  Performance status
   Good −0.237 0.053 −0.508 0.160
  Disease stage
   IIIA 0.242 0.081
   IIIB 0.384 0.083
Mean 2Y probabilityd
  CRT 62% 18%
  VART 56% 18%
  MART 56% 18%
  HRTI 57% 18%
  HRTH 61% 18%
Source MAR-LC MAR-LC
aIncluded in the probabilistic sensitivity analysis using a multivariate normal 
distribution which was constructed using Cholesky decompositions (multivariate normal 
distribution).4
bCalculated using the following formula: −Ln(scale) × shape.
cHistology was excluded (according to the purposeful selection of covariates 
algorithm by Hosmer and Lemeshow).1,5
dThis probability represents the mean 2-yr probability for the separate Weibull 
models (not the 2-yr probability as in the Markov trace).
2Y = 2-yr; CRT, conventional fractionation radiotherapy; HRTI, identical 
hyperfractionated radiotherapy; HRTH, higher hyperfractionated radiotherapy; VART, 
very accelerated radiotherapy; MART, moderately accelerated radiotherapy; MAR-LC, 
Meta-Analysis of Radiotherapy in Lung Cancer.
APPENDIx 3. Input Parameters for Acute Toxicity
The included covariates and subsequent selection proce-
dure were the same for acute pulmonary and esophageal toxic-
ity as described for the Weibull models (Appendix 2). This was 
also the case for hematological toxicity, except that the treat-
ment arm was excluded as covariate because it is caused by che-
motherapy and independent of radiation fractionation scheme. 
The parameterization of the logistic model is as follows:
 p
e
e
z
z
=
+1
 (1)
Where p is the toxicity probability and z was calculated 
by the sum of all coefficients multiplied by the accompanying 
covariates (X): 
 
z X
X
Intercept Treament arm Treatment arm
Age 6 69 Age 6
= +
+ −
β β
β 0 0 0 0− + ++
+ +
69 Age 7 Age 7
Female Female Performance status 
X
X
β
β β good Performance status good
Histology Squamous cell His
X
X+β tology Squamous cell
Disease Stage IIIA Disease Stage IIX+β IA Disease Stage IIIB Disease Stage IIIBX+β
 (2)
As for the Weibull models, the logistic regression models 
were stratified by trial. However, no coefficient for the intercept 
is given if the logistic regression models are stratified by trial in 
SAS, thus absolute toxicity probabilities based could not be cal-
culated based on this logistic regression model. Therefore, sep-
arate logistic regression models were constructed for each trial 
using the covariates as selected in the above described logistic 
regression model stratified by trial. The obtained coefficients 
for each trial were pooled using a random-effects model.3 To 
calculate the acute toxicity probabilities using the logistic 
regression models, individual characteristics were needed. For 
this purpose, a hypothetical cohort of individual patients with 
individual characteristics was replicated based on the aver-
age characteristics and their correlations from the MAR-LC-
database. For each patient, the individual z values and toxicity 
probabilities were calculated. To obtain the toxicity probabili-
ties for the whole cohort, the individual probabilities were aver-
aged. This was done separately for each comparator.
Estimated Regression Coefficients for Acute Toxicity (≥Grade 
3) Probabilitiesa
Parameter Equation 1: 
Probability of 
Acute Pulmonary 
Toxicity (77 
Events)b
Equation 2: 
Probability of 
Acute Esophageal 
Toxicity (304 
Events)
Equation 3: 
Probability 
of Acute 
Hematological 
Toxicity (202 
Events)
Estimated 
Value
SE Estimated 
Value
SE Estimated 
Value
SE
Explanatory baseline characteristicsc
 Intercept −2.856 0.273 −2.429 0.268 −1.892 1.418
 Trial arm
  VART −0.625 0.324 1.281 0.216
  MART/HRTH 0.086 0.405 0.428 0.539
  HRTI 0.016 0.839 −0.157 0.314
 Age (yr)
  60–69 0.360 0.323 0.364 0.560
  70+ 0.737 0.354 1.033 0.374
 Sex
  Female 0.672 0.204 0.963 0.313
Mean probabilityd
 CRT 7.8% 9.8% 24.7%e
 VART 4.4% 27.8% 24.7%e
 MART/HRTH 8.5% 14.3% 24.7%e
 HRTI 8.0% 8.6% 24.7%e
Source MAR-LC MAR-LC MAR-LC
aIncluded in the probabilistic sensitivity analysis using a multivariate normal distribution 
which was constructed using Cholesky decompositions (multivariate normal distribution).4
bTo handle the occurrence of zero events in 2 × 2 tables between dependent and 
independent variables (leading to quasicomplete separation), the Firth’s penalized 
maximum likelihood estimation method6,7 was used for four logistic regression models.
cA combined estimate was calculated for HRTH and MART. This was done because 
acute toxicity was not reported in the MART trial and the overall treatment time and total 
treatment dose are similar for these two comparators In addition, performance status, 
histology and disease stage were excluded (according to the purposeful selection of 
covariates algorithm by Hosmer and Lemeshow).1,5
dIt was assumed that acute toxicity increased from start radiotherapy to 3 months 
thereafter to the total probability (reported in the table). The monthly probability was 
then calculated from the total probability using the following formula:4
p
p
1 month   1  e 
ln 1   total   1 3( ) = − − ( )( )×( )/
eHematological toxicity is mainly caused by the administration of chemotherapy 
rather than the radiotherapy treatment scheme and was therefore assumed to be 
independent of the radiotherapy scheme (and thus equal for all comparators). The 
calculated probability (24.7%) was conditional on that patients received chemotherapy 
and has to be multiplied by the proportion of patients who received chemotherapy 
(29.5%; assumed equal among all comparators) to calculate the average probability of 
acute hematological toxicity per comparator (7.3%).
CRT, conventional fractionation radiotherapy; HRTI, identical hyperfractionated 
radiotherapy; HRTH, higher hyperfractionated radiotherapy; VART, very accelerated 
radiotherapy; MART, moderately accelerated radiotherapy; MAR-LC, Meta-Analysis of 
Radiotherapy in Lung Cancer.
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APPENDIx 4. Cost-Effectiveness Planes Corresponding to 
the Comparison in Table 3
HRTH versus CRT
% Simulations
North-west quadrant 44.0
North-east quadrant 56.0
South-west quadrant 0.0
South-east quadrant 0.0
HRTH cost effective 35.2
CRT cost effective 64.8
The diagonal line represents the ceiling ratio which was adopted in our analyses 
(€80,000 per QALY gained).
HRTH, hyperfractionated radiotherapy using higher total treatment dose as 
conventional radiotherapy; CRT, conventional fractionation radiotherapy.
HRTI versus CRT
% Simulations
North-west quadrant 14.5
North-east quadrant 85.5
South-west quadrant 0.0
South-east quadrant 0.0
HRTI cost effective 80.7
CRT cost effective 19.3
The diagonal line represents the ceiling ratio which was adopted in our analyses 
(€80,000 per QALY gained).
CRT, conventional fractionation radiotherapy; HRTI, identical hyperfractionated 
radiotherapy.
VART versus CRT
% Simulations
North-west quadrant 0.4
North-east quadrant 99.6
South-west quadrant 0.0
South-east quadrant 0.0
VART cost effective 99.1
CRT cost effective 0.9
The diagonal line represents the ceiling ratio which was adopted in our analyses 
(€80,000 per QALY gained).
CRT, conventional fractionation radiotherapy; HRTI, hyperfractionated radiotherapy 
using identical total treatment dose as conventional radiotherapy; VART, very accelerated 
radiotherapy.
MART Versus CRT
% Simulations
North-west quadrant 27.3
North-east quadrant 82.6
South-west quadrant 0.0
South-east quadrant 0.1
MART cost effective 69.7
CRT cost effective 30.3
The diagonal line represents the ceiling ratio, which was adopted in our analyses 
(€80,000 per QALY gained).
CRT, conventional fractionation radiotherapy; MART, moderately accelerated 
radiotherapy.
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VART versus HRTI
% Simulations
North-west quadrant 2.1
North-east quadrant 0.0
South-west quadrant 38.5
South-east quadrant 59.4
VART cost effective 60.6
HRTI cost effective 39.4
The diagonal line represents the ceiling ratio which was adopted in our analyses 
(€80,000 per QALY gained).
VART, very accelerated radiotherapy; identical hyperfractionated radiotherapy.
MART versus VART
% Simulations
North-west quadrant 50.3
North-east quadrant 39.0
South-west quadrant 0.0
South-east quadrant 10.7
MART cost effective 51.0
VART cost effective 49.0
The diagonal line represents the ceiling ratio which was adopted in our analyses 
(€80,000 per QALY gained).
MART, moderately accelerated radiotherapy; VART, very accelerated radiotherapy.
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